CG
REGN icon

Caprock Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Caprock Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.14M Sell
2,768
-133
-5% -$102K 0.05% 323
2025
Q4 		$2.24M Buy
2,901
+373
+15% +$253K 0.05% 344
2025
Q3 		$1.47M Buy
+2,528
New +$1.43M 0.04% 439
2025
Q1 		$758K Sell
1,195
-452
-27% -$311K 0.02% 559
2024
Q4 		$1.17M Buy
1,647
+351
+27% +$295K 0.04% 383
2024
Q3 		$1.36M Sell
1,296
-90
-6% -$100K 0.05% 320
2024
Q2 		$1.46M Buy
1,386
+521
+60% +$505K 0.06% 285
2024
Q1 		$833K Buy
865
+68
+9% +$64.7K 0.05% 286
2023
Q4 		$700K Sell
797
-153
-16% -$126K 0.04% 305
2023
Q3 		$782K Sell
950
-148
-13% -$116K 0.06% 259
2023
Q2 		$789K Buy
1,098
+188
+21% +$145K 0.06% 262
2023
Q1 		$748K Buy
910
+240
+36% +$181K 0.06% 255
2022
Q4 		$483K Buy
670
+132
+25% +$97.4K 0.05% 290
2022
Q3 		$371K Buy
538
+66
+14% +$41.5K 0.04% 355
2022
Q2 		$279K Sell
472
-5
-1% -$3.25K 0.03% 403
2022
Q1 		$333K Buy
477
+40
+9% +$25.3K 0.03% 385
2021
Q4 		$276K Sell
437
-13
-3% -$7.99K 0.02% 457
2021
Q3 		$272K Buy
450
+44
+11% +$27.3K 0.02% 411
2021
Q2 		$227K Buy
+406
New +$206K 0.02% 467
2021
Q1 		– Sell
-426
Closed -$206K – 526
2020
Q4 		$206K Sell
426
-146
-26% -$78.8K 0.02% 442
2020
Q3 		$320K Buy
572
+156
+38% +$94.6K 0.04% 281
2020
Q2 		$259K Buy
+416
New +$236K 0.04% 314

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Caprock Group's REGN Position: Q1 2026 in Review

Caprock Group reduced its Regeneron Pharmaceuticals (REGN) stake by 4.6% in Q1 2026, selling an estimated $102K and leaving 2,768 shares worth $2.14M. The position accounts for 0.05% of the portfolio, ranked #323.

Caprock Group first reported a position in REGN in Q2 2020 and has held it in 22 quarters since. The position peaked at $2.24M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Caprock Group held 2,768 shares of Regeneron Pharmaceuticals worth $2.14M as of Q1 2026.
  • Caprock Group sold 133 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $102K.
  • Regeneron Pharmaceuticals made up 0.05% of Caprock Group's portfolio in Q1 2026, its #323 holding.
  • Caprock Group first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • Caprock Group's Regeneron Pharmaceuticals position peaked at $2.24M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.